Pharmacological Inhibition of Lactation After 16 to 20 Week Abortion

Part of paid clinical trials in Chicago, Illinois.

Sponsor
Northwestern University
Study ID
NCT06123026
Phase
PHASE4
Status
Recruiting
Apply to this trial

Conditions

  • Lactation Suppressed
  • Second Trimester Abortion

Eligibility Criteria

Sex
FEMALE
Age
18 Years - 50 Years
Healthy Volunteers
Accepted

Interventions

  • Cabergoline — DRUG
    1mg oral cabergoline given to participants once
  • Placebo — DRUG
    1 encapsulated placebo tablet given to participants after procedure

Study Details

The goal of this clinical trial is to compare breast symptoms (lactation, engorgement, etc) of individuals who undergo a procedure for second trimester of pregnancy loss between 16 weeks and 20 weeks gestational age. The participants will be randomly placed in two groups, one with a placebo tablet and one with medication called "cabergoline" which are taken immediately after their procedure. Researchers will compare groups to see if there are any significant differences in breast symptoms.

Key Dates

Start date
Dec 18, 2023
Status verified
May 2024
Primary completion
Jun 30, 2024
Completion
Jun 30, 2024

Study Design

Enrollment
200 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Cabergoline
    1mg oral cabergoline administered once after patient's procedure
  • Placebo Comparator: Placebo
    1 tablet encapsulated placebo by Investigational Drug Pharmacy administered once after patient's procedure

Primary Outcome Measure

breast symptoms [ Time Frame: 3 days post procedure and two weeks post procedure ]

Locations (1)

FacilityCityStateZIPSite coordinators
Northwestern Medical CenterChicagoIllinois60611
Leanne McCloskey
[email protected]
312-926-8678

Find similar trials in Chicago, IL

By research site
Northwestern Medical Center· Chicago, IL

Related Studies